Solixant is, above all, R & D-center established for the transfer of the parent company's technology in Russia, which specializes in the study and analysis of strains of microalgae from Russian collections, followed by the creation of pilot production of drugs, food additives, feed biomass for aquaculture and more.

At present the laboratory "Soliksant" is developing three major projects related to the study of algae. Projects implemented jointly with leading biotechnology institutions.

Green medicine
Search "green" classical analogues of drugs from the biomass of microalgae and cyanobacteria

The project is dedicated to finding new antibiotics from the biomass of microalgae and cyanobacteria.

The aim of the project is to study a broad panel of cultures of microalgae and cyanobacteria as producers of commercially attractive new generation of antibiotics.

For mass screening of producers of new antibiotics, the company "Soliks Biosystems" will use "iChip" technology, adapted for phototrophic microorganisms. Then in photobioreactors company will assess the ability of the industrial cultivation of the most efficient producers of antibiotics.

Starter feed for aquaculture
Creation of omega-3 unsaturated composite feed for aquaculture based on microalgae

"Soliksant" together with agro-biological cluster Skolkovo IC creates "omega-3 rich composite feed for aquaculture based on microalgae."

Microalgae are natural sources of omega-3 polyunsaturated fatty acids in fish carotenoid antioxidants. "Soliksant" is the only Russian company, which has strains of algae that are able to synthesize both of these components for the production of high-quality additives in animal feed.

The resulting product will have a higher stability, will not contain GMOs and can be used for breeding juvenile aquaculture species.

The search for new antibiotics from microalgae and cyanobacteria

The project aims to find "green" for the classical analogues lekartsvennyh funds on the market.

The project is a comparative analysis of the effect of microalgal extracts and classical drugs (approved by the FDA) with different target exposure. A comparison will take place at the transcriptome level; as a model for various human cell lines is used.

The project is implemented jointly with the company "CRCH" and the Broad Institute of MIT and Harvard.

Scheme study of microalgae

Микроводоросли изучаются в «Соликсант» при помощи единой схемы, состоящей из трех шагов
Step 1

Selection of the research object. They may be a strain from the collection of the leading specialized research institutes, and assembled by our own in the wild.

In the second case, a preliminary sample collection and isolation of algae in pure culture algological.

Step 2

Accretion algal biomass in an amount sufficient to study basic properties of this strain. Analysis nakaplivaemmyh inside the cells and excreted molecules.

Particular attention is given to polyunsaturated fatty acids, the pigment composition, substances with antibiotic properties.

Step 3

The most promising are selected for cultivation of microorganisms in photobioreactors.

An evaluation of several biotechnological parameters that we can indicate how the strain is promising from the standpoint of obtaining the target component in an industrial scale.


The result is not only to detect strain producing a commercially attractive compounds and experimental-industrial regulations cultivation of a particular microorganism, which can be claimed, and other biotech companies.